ARID2

AT-rich interactive domain-containing protein 2 · Q68CP9 · ARID2 on Sugi Atlas →

0 patent compounds predicted against ARID2, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to ARID2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients PHASE3UNKNOWN
Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD PHASE3COMPLETED
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation PHASE2UNKNOWN
Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer PHASE2ACTIVE_NOT_RECRUITING
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors. PHASE2RECRUITING
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation PHASE2UNKNOWN
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma PHASE2RECRUITING
Simvastatin Efficacy in ARID1A Mutated Advanced gastroESophageal Carcinoma Treated With Immunotherapy PHASE2RECRUITING
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer PHASE1RECRUITING
Evaluating Safety & Efficacy Belinostat Combo w Nivo Alone & w Ipi in Patients w Treated Metastatic/Advanced Carcinomas w ARID1A Lof Mutation PHASE1WITHDRAWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Discovery and Validation of Plasma DNA Methylation Biomarker for Detection of Stomach Cancer nanCOMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Epigenomic Profiling of Circulating Cell-Free DNA (cfDNA) to Characterize the Dynamic Evolution of Molecular Subtypes in Extensive-Stage Small Cell Lung Cancer During First-Line Chemoimmunotherapy nanNOT_YET_RECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Studying Gene Expression in Samples From Patients With Rhabdoid Tumors nanCOMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Next-Generation Sequencing-based Germline and Somatic Genetic Testing in Triple-negative Breast Cancer nanUNKNOWN
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA nanRECRUITING
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
Genetic Variation in TRAF3IP2 (rs13190932) nanRECRUITING
Genetic of SportS Induced Endofibrotic Remodeling nanCOMPLETED
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia nanCOMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a ARID2 binder may also engage these)

ProteinNameSimilarity
E9Q7E2 0.998 E9Q7E2 →
Q5RER5 0.993 Q5RER5 →
P58462 0.992 P58462 →
D9PTN5 0.992 D9PTN5 →
Q58NQ4 0.991 Q58NQ4 →
P41846 0.991 P41846 →
Q92540 0.990 Q92540 →
Q99P99 0.990 Q99P99 →
Q3T1I5 0.990 Q3T1I5 →
P23899 0.990 P23899 →
Q94361 0.990 Q94361 →
Q3L1C9 0.989 Q3L1C9 →
Q9H334 0.989 Q9H334 →
Q66J63 0.989 Q66J63 →
P20912 0.989 P20912 →
Q08639 0.989 Q08639 →
P24610 0.989 P24610 →
Q6GN21 0.989 Q6GN21 →
Q91857 0.989 Q91857 →
O60167 0.989 O60167 →
P22361 0.989 P22361 →
Q9P2R6 0.989 Q9P2R6 →
P28700 0.989 P28700 →
Q172Y1 0.989 Q172Y1 →
Q33E94 0.988 Q33E94 →
Q04727 0.988 Q04727 →
Q7ZX03 0.988 Q7ZX03 →
P40426 0.988 P40426 →
NFRKB Nuclear factor related to kappa-B-binding protein 0.988 landscape →
A0A0J9UPF5 0.988 A0A0J9UPF5 →